Life sciences clause bank

Discover essential clauses for life sciences contracts that cater to the distinct needs of the industry. Our comprehensive clause bank offers expertly drafted provisions, ensuring your agreements are robust and compliant. Whether handling clinical trials, intellectual property, or regulatory matters, utilise precise contract language to safeguard your interests and streamline negotiations.

View Life Sciences by content type:

News
Practice notes
Precedents
Q&As

Sub Topics We Cover

Boilerplate clauses Definitions Execution Life sciences clauses

Latest Life Sciences News

AI model providers get confirmation of delays to EU Code of Practice

AI model providers get confirmation of delays to EU Code of Practice

The following EU Law news provides comprehensive and up to date legal information on AI model providers get confirmation of delays to EU Code of Practice

Implement PMSV reporting forms

Implement PMSV reporting forms
Court of Appeal considers the interpretation of condition precedent clauses in Disclosure and Barring Service v Tata Consultancy Services Ltd

Court of Appeal considers the interpretation of condition precedent clauses in Disclosure and Barring Service v Tata Consultancy Services Ltd

The following Commercial news provides comprehensive and up to date legal information on Court of Appeal considers the interpretation of condition precedent clauses in Disclosure and Barring Service v Tata Consultancy Services Ltd

Enhance EU medical devices regulation

Enhance EU medical devices regulation

Featured Life Sciences content

The regulation of medical devices in the UK

The regulation of medical devices in the UK

The regulation of medical devices in the UKThis Practice Note provides an overview of the UK regulatory regime for medical devices. It explains the...

Regulation of e-cigarettes

Regulation of e-cigarettes

Regulation of e-cigarettes31 December 2020 marked the end of the Brexit implementation period following the UK’s decision to withdraw from the EU. At...

Clinical evaluation and performance evaluation of medical devices in the EU

Clinical evaluation and performance evaluation of medical devices in the EU

Clinical evaluation and performance evaluation of medical devices in the EUThis Practice Note describes key changes to the requisite clinical...

Unlicensed medicinal products and off-label use of medicinal products

Unlicensed medicinal products and off-label use of medicinal products

Unlicensed medicinal products and off-label use of medicinal productsThis Practice Note explores unlicensed medicinal products and the various ways...

Practice notes

Second and subsequent medical use patent claims

Second and subsequent medical use patent claimsBackground to medical use claimsSecond (and subsequent) medical use patent claims are specific to the...
Read More >
Produced in partnership with Andrew Bowler of Bristows and Adrian Chew of Bristows
28th Mar
Practice notes

Post-market surveillance of medical devices in the EU

Post-market surveillance of medical devices in the EUPost-market surveillance is the monitoring by manufacturers of medical devices to ensure their...
Read More >
Produced in partnership with Alison Dennis of Taylor Wessing LLP
28th Mar
Practice notes

Intellectual property protection for medical devices

Intellectual property protection for medical devicesChanges to intellectual property (IP) law from 1 January 2021Before discussing how intellectual...
Read More >
Produced in partnership with Reuben E. Jacob of Maucher Jenkins and Dr Edward Rainsford of Maucher Jenkins
28th Mar
Practice notes

Medicines and Medical Devices Act 2021

Medicines and Medical Devices Act 2021This Practice Note provides an overview of the Medicines and Medical Devices Act 2021 (MMDA 2021) which, in...
Read More >
1st Mar
tag iconBrexit
Practice notes

Introduction to borderline products

Introduction to borderline productsThis Practice Note provides an introduction to the concept of borderline products, how the regulatory status of...
Read More >
2nd Mar
Precedents

Clinical Research Organisation (CRO) master services agreement

Clinical Research Organisation (CRO) master services agreementDATA PROTECTION NOTICE: Please note that the drafting of clause 7 (Data Protection), in...
Read More >
1st Mar
Practice notes

Pharmacovigilance

PharmacovigilancePharmacovigilance is the process of collecting and understanding information relating to the adverse effects of medicinal product...
Read More >
Produced in partnership with Eveline Van Keymeulen of Latham & Watkins and Jeanne Fabre of Latham & Watkins
28th Mar
News

The UK medical devices regime and the impact of the Northern Ireland Protocol

Life Sciences analysis: Peter Rudd-Clarke, partner, and Anna Lundy, associate director, at Osborne Clarke discuss how the medical device industry is...
Read More >
2nd Mar
Precedents

Medical devices due diligence questionnaire

Medical devices due diligence questionnaireIntroductionThis medical devices regulatory due diligence questionnaire relates to the proposed purchase by...
Read More >
2nd Mar
News

Life Sciences weekly highlights—11 August 2022

This week's edition of Life Sciences weekly highlights includes analysis of the English court’s jurisdiction to decide COVID-related business...
Read More >
2nd Mar
Practice notes

The regulation of advanced therapy medicinal products

The regulation of advanced therapy medicinal productsThe development of medicine, biomicrobiology and biotechnology has led to the emergence of a...
Read More >
Produced in partnership with Geneviève Michaux of King & Spalding
28th Mar
Practice notes

The experimental use and Bolar-type exemptions to patent infringement

The experimental use and Bolar-type exemptions to patent infringementPatent systems are intended to foster innovation, not to impede it. For this...
Read More >
Produced in partnership with Selina Badiani of Bristows and Charlie French of Bristows LLP
28th Mar
tag iconIn-house
News

Life Sciences weekly highlights—18 August 2022

This week's edition of Life Sciences weekly highlights includes consideration of the arguments put forward against DeepMind, Google’s subsidiary, for...
Read More >
2nd Mar
Practice notes

Pharma and medical device regulation—Colombia—Q&A guide

Pharma and medical device regulation—Colombia—Q&A guideThis Practice Note contains a jurisdiction-specific Q&A guide to pharma and medical...
Read More >
2nd Mar
Practice notes

Biotechnology patents

Biotechnology patentsPatenting biotechnological inventionsBiotechnological inventions are, in principle, patentable. While there is no general...
Read More >
Produced in partnership with Nicole Jadeja of Pinsent Masons and Christopher Leung of Fieldfisher
28th Mar
Practice notes

The EU Clinical Trials Regulation

The EU Clinical Trials RegulationThis Practice Note looks at Regulation (EU) 536/2014, the EU Clinical Trials Regulation (CTR), which governs clinical...
Read More >
Produced in partnership with Eveline Van Keymeulen of Latham & Watkins
28th Mar

Popular documents

Financial clean break orders in family proceedings

Financial clean break orders in family proceedingsDuty of the court to consider a clean breakAlthough there is no presumption in favour of there being a financial clean break between parties on divorce, the court is under a duty to consider whether it would be appropriate to exercise its powers so

Late payment penalties—inheritance tax

Late payment penalties—inheritance taxWhile interest often accrues on overdue tax, the late payment of certain taxes may also attract a penalty. For information on the interest accruing on overdue tax, see Practice Notes: IHT—payment deadlines on death—Interest on IHT and Interest on late paid

Brussels I (recast)—domicile (Arts 4 and 63) [Archived]

Brussels I (recast)—domicile (Arts 4 and 63) [Archived]ARCHIVED: This Practice Note has been archived and is not maintained.This Practice Note considers the general rule set out in Article 4 of Regulation (EU) 1215/2012, Brussels I (recast) when determining the relevance of a defendant’s domicile to

Where are misrepresentations made? Jurisdictional traps for the unwary (Bellmare Holdings Ltd v Wells)

Dispute Resolution analysis: The High Court has provided concise guidance as to how misrepresentation should be analysed when considering jurisdictional gateways. Under Article 5(3) of the Lugano Convention, in negligent misstatement cases, the place of the event giving rise to damage is normally